Elevance Health Inc's Suppliers recorded an increase in sales by 13.24 % year on year in Q3 2026, sequentially sales grew by 4.52 %, Elevance Health Inc recorded an increase in cost of sales by 4.83 % year on year, sequentially cost of sales grew by 2.69 % in Q3.
Elevance Health Inc's Suppliers recorded an increase in sales by 13.24 % year on year in Q3 2026, sequentially sales grew by 4.52 %, Elevance Health Inc recorded increase in cost of sales by 4.83 % year on year, sequentially cost of sales grew by 2.69 % in Q3.
The pharmacy services business depends on pharmacy services suppliers and third-party vendors, all of whom must comply with various federal and state laws and regulations governing pharmaceutical dispensing. These include anti-kickback laws, beneficiary inducement laws, consumer protection laws, ERISA, HIPAA, and regulations related to mail-service pharmacies. The business operates through home delivery, infusion, and specialty pharmacies and is subject to licensure, registration, and regulatory requirements from state boards of pharmacy, state-controlled substance authorities, the U.S. Drug Enforcement Agency, and the U.S. Food and Drug Administration. Noncompliance by the company or its suppliers could adversely affect the business. Additionally, new and evolving laws and regulations concerning pricing, rebates, formularies, pharmacy benefit managers, and state-specific regulations, such as recent legislation in California, may further impact operations. Government investigations into pharmacy services practices have resulted in civil penalties and corporate integrity agreements for pharmacy benefit managers, which could influence the business model.
Elevance Health Inc's Comment on Supply Chain
The pharmacy services business depends on pharmacy services suppliers and third-party vendors, all of whom must comply with various federal and state laws and regulations governing pharmaceutical dispensing. These include anti-kickback laws, beneficiary inducement laws, consumer protection laws, ERISA, HIPAA, and regulations related to mail-service pharmacies. The business operates through home delivery, infusion, and specialty pharmacies and is subject to licensure, registration, and regulatory requirements from state boards of pharmacy, state-controlled substance authorities, the U.S. Drug Enforcement Agency, and the U.S. Food and Drug Administration. Noncompliance by the company or its suppliers could adversely affect the business. Additionally, new and evolving laws and regulations concerning pricing, rebates, formularies, pharmacy benefit managers, and state-specific regulations, such as recent legislation in California, may further impact operations. Government investigations into pharmacy services practices have resulted in civil penalties and corporate integrity agreements for pharmacy benefit managers, which could influence the business model.
ELV's Suppliers Net Income grew by
ELV's Suppliers Net margin grew in Q3 to
24.78 %
20.95 %
ELV's Suppliers Net Income grew by 24.78 %
ELV's Suppliers Net margin grew in Q3 to 20.95 %
Elevance Health Inc's Suppliers Sales Growth
in Q3 2026 by Industry
Sources:
Elevance Health Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Elevance Health Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
32.77 %